LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Presents Intelligent Diagnostic Solutions at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: Siemens gave live demonstrations of its Atellica Solution at AACC 2022 (Photo courtesy of Siemens Healthineers)
Image: Siemens gave live demonstrations of its Atellica Solution at AACC 2022 (Photo courtesy of Siemens Healthineers)

Siemens Healthineers (Erlangen, Germany) is showcasing its “Continuous innovation for a lifetime of answers” at the 2022 AACC Clinical Lab Expo where the company will display and demonstrate various solutions for the clinical lab.

At AACC 2022, Siemens is holding live demonstrations of its Atellica Solution comprising flexible, scalable, automation-ready immunoassay and chemistry analyzers with integrated automation in 6m2. This includes its Atellica Integrated Automation (AIA) on the Atellica Solution that consolidates revolutionary sample management technology, intelligent software, and IT to provide workflow efficiency with the flexibility to add decapping with little or no additional footprint. Siemens will also demonstrate its automation solutions that are fully scalable, innovative, and customized for workflow for labs of all sizes. This includes its Aptio Automation solution which combines intelligent technologies with Siemens’ workflow expertise to deliver flexible solutions that advance laboratory productivity. Siemens is also demonstrating Atellica Task Targeted Automation that can drive open, one-touch sample preparation for multidisciplinary labs and Atellica Integrated Automation that can streamline a lab’s biggest chemistry and immunoassay workloads.

Siemens is also displaying its portfolio of chronic disease management solutions that provides fast, reliable, and accurate results at the point of care. This includes the Atellica DCA Analyzer for fast, quality HbA1c and ACR results at the fingertips, the CLINITEK Status Connect System with Auto-Checks Technology that simplifies and streamlines daily operations, and the POC Ecosystem Solution designed to help manage the complete POCT process across the healthcare continuum. In addition, Siemens is highlighting the Atellica 1500 Automated Urinalysis System that combines the CLINITEK Novus automated urine chemistry analyzer and the Atellica UAS 800 urine sediment analyzer in one completely automated unit.

In the field of critical care testing, Siemens is demonstrating the epoc Blood Analysis System that delivers critical testing results securely at patient-side in less than one minute. The system also connects the entire care team so it doesn’t matter if the laboratory staff and caregivers work in different parts of the hospital. Within its portfolio of innovative assays, Siemens will present the Atellica IM B·R·A·H·M·S procalcitonin assay that helps achieve early sepsis risk assessment and aids in the management of antibiotic therapy. Siemens is also highlighting the Neurofilament light chains (sNfL) assay that is intended to be used as an aid in identifying adult patients with relapsing multiple sclerosis who are at lower vs. higher risk of MS disease activity. Visitors to the Siemens AACC booth will be introduced to the Enhanced Liver Fibrosis (ELF) Test, which is the first and only biomarker to be granted FDA De Novo marketing authorization for prognosis of patients with advanced fibrosis due to non-alcoholic steatohepatitis (NASH).
 

Related Links:
Siemens Healthineers 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Sekisui Diagnostics UK Ltd.